Differential DNA methylation status between breast carcinomatous and normal tissues

Biomedicine and Pharmacotherapy

Volumn 68, Issue 6, 2014, Pages 699-707

  Wang, Fengliang ^a   Yang, Yafang ^b   Fu, Ziyi ^a   Xu, Nan ^c   Chen, Fei ^a   Yin, Hong ^a   Lu, Xun ^d   Shen, Rong ^a   Lu, Cheng ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b THE SECOND AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^c NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

^d Jinling High School   (China)

Author keywords

Breast cancer; DNA methylation; Microarray

Indexed keywords

PROTEIN; PROTEIN CRABP 1; PROTEIN HOXB 13; PROTEIN IFNGR 2; PROTEIN PIK3C3; UNCLASSIFIED DRUG;

ARTICLE; BREAST; BREAST CARCINOMA; CLINICAL ARTICLE; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; FEMALE; GENE MUTATION; GENE ONTOLOGY; HUMAN; HUMAN TISSUE; METHYLATION SPECIFIC POLYMERASE CHAIN REACTION; POLYMERASE CHAIN REACTION; PROMOTER REGION; TRANSCRIPTION INITIATION SITE; BREAST TUMOR; COMPARATIVE STUDY; GENE REGULATORY NETWORK; GENETICS; METABOLISM; MIDDLE AGED; PHYSIOLOGY;

BREAST; BREAST NEOPLASMS; DNA METHYLATION; FEMALE; GENE REGULATORY NETWORKS; HUMANS; MIDDLE AGED;

EID: 84908087753     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2014.07.014     Document Type: Article

References (53)

1. Forouzanfar M.H., Foreman K.J., Delossantos A.M., Lozano R., Lopez A.D., Murray C.J., et al. Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis. Lancet 2011, 378(9801):1461-1484.
2. Hayes D.F., Isaacs C., Stearns V. Prognostic factors in breast cancer: current and new predictors of metastasis. J Mammary Gland Biol Neoplasia 2001, 6(4):375-392.
3. Feinberg A.P., Ohlsson R., Henikoff S. The epigenetic progenitor origin of human cancer. Nat Rev Genet 2006, 7(1):21-33.
4. Bergman Y., Cedar H. DNA methylation dynamics in health and disease. Nat Struct Mol Biol 2013, 20(3):274-281.
5. Sanchez-Cespedes M., Esteller M., Wu L., Nawroz-Danish H., Yoo G.H., Koch W.M., et al. Gene promoter hypermethylation in tumors and serum of head and neck cancer patients. Cancer Res 2000, 60(4):892-895.
6. Yang G., Zhang H., Liu Y., Zhou J., He W., Quick C.M., et al. Epigenetic and immunohistochemical characterization of the Clusterin gene in ovarian tumors. Arch Gynecol Obstet 2013, 287(5):989-995.
7. Zhao H., Li Q., Wang J., Su X., Ng K.M., Qiu T., et al. Frequent epigenetic silencing of the folate-metabolising gene cystathionine-Beta-synthase in gastrointestinal cancer. PLoS One 2012, 7(11):e49683.
8. Jones P.A., Baylin S.B. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002, 3(6):415-428.
9. Feinberg A.P., Tycko B. The history of cancer epigenetics. Nat Rev Cancer 2004, 4(2):143-153.
10. Docherty S.J., Davis O.S., Haworth C.M., Plomin R., Mill J. DNA methylation profiling using bisulfite-based epityping of pooled genomic DNA. Methods 2010, 52(3):255-258.
11. Esteller M. Epigenetics in cancer. N Engl J Med 2008, 358(11):1148-1159.
12. Rauch T.A., Pfeifer G.P., The M.I.R.A. method for DNA methylation analysis. Methods Mol Biol 2009, 507:65-75.
13. Rauch T.A., Wu X., Zhong X., Riggs A.D., Pfeifer G.P. A human B-cell methylome at 100-base pair resolution. Proc Natl Acad Sci U S A 2009, 106(3):671-678.
14. Edge S.B., Compton C.C. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010, 17(6):1471-1474.
15. Falcon S., Gentleman R. Using GOstats to test gene lists for GO term association. Bioinformatics 2007, 23(2):257-258.
16. Fury W., Batliwalla F., Gregersen P.K., Li W. Overlapping probabilities of top ranking gene lists, hypergeometric distribution, and stringency of gene selection criterion. Conf Proc IEEE Eng Med Biol Soc 2006, 1:5531-5534.
17. Rodenhiser D.I., Andrews J., Kennette W., Sadikovic B., Mendlowitz A., Tuck A.B., et al. Epigenetic mapping and functional analysis in a breast cancer metastasis model using whole-genome promoter tiling microarrays. Breast Cancer Res 2008, 10(4):R62.
18. Blake J.A., Dolan M., Drabkin H., Hill D.P., Ni L., Sitnikov D., et al. The gene ontology: enhancements for 2011. Nucleic Acids Res 2012, 40(Database issue):D559-D564.
19. Ashburner M., Ball C.A., Blake J.A., Botstein D., Butler H., Cherry J.M., et al. Gene ontology: tool for the unification of biology. Nat Genet 2000, 25(1):25-29.
20. Dupuy D., Bertin N., Hidalgo C.A., Venkatesan K., Tu D., Lee D., et al. Genome-scale analysis of in vivo spatiotemporal promoter activity in Caenorhabditis elegans. Nat Biotechnol 2007, 25(6):663-668.
21. Schlitt T., Palin K., Rung J., Dietmann S., Lappe M., Ukkonen E., et al. From gene networks to gene function. Genome Res 2003, 13(12):2568-2576.
22. Yi M., Horton J.D., Cohen J.C., Hobbs H.H., Stephens R.M. WholePathwayScope: a comprehensive pathway-based analysis tool for high-throughput data. BMC Bioinformatics 2006, 7:30.
23. Draghici S., Khatri P., Tarca A.L., Amin K., Done A., Voichita C., et al. A systems biology approach for pathway level analysis. Genome Res 2007, 17(10):1537-1545.
24. Jansen R., Greenbaum D., Gerstein M. Relating whole-genome expression data with protein-protein interactions. Genome Res 2002, 12(1):37-46.
25. Li C., Li H. Network-constrained regularization and variable selection for analysis of genomic data. Bioinformatics 2008, 24(9):1175-1182.
26. Wei Z., Li H. A Markov random field model for network-based analysis of genomic data. Bioinformatics 2007, 23(12):1537-1544.
27. Zhang J.D., Wiemann S. KEGGgraph: a graph approach to KEGG PATHWAY in R and bioconductor. Bioinformatics 2009, 25(11):1470-1471.
28. Spirin V., Mirny L.A. Protein complexes and functional modules in molecular networks. Proc Natl Acad Sci U S A 2003, 100(21):12123-12128.
29. Huang Y., Nayak S., Jankowitz R., Davidson N.E., Oesterreich S. Epigenetics in breast cancer: what's new?. Breast Cancer Res 2011, 13(6):225.
30. Abramovich C., Humphries R.K. Hox regulation of normal and leukemic hematopoietic stem cells. Curr Opin Hematol 2005, 12(3):210-216.
31. Iimura T., Pourquie O. Hox genes in time and space during vertebrate body formation. Dev Growth Differ 2007, 49(4):265-275.
32. Moens C.B., Selleri L. Hox cofactors in vertebrate development. Dev Biol 2006, 291(2):193-206.
33. Pilato B., Pinto R., De Summa S., Lambo R., Paradiso A., Tommasi S. HOX gene methylation status analysis in patients with hereditary breast cancer. J Hum Genet 2013, 58(1):51-53.
34. Chu M.C., Selam F.B., Taylor H.S. HOXA10 regulates p53 expression and matrigel invasion in human breast cancer cells. Cancer Biol Ther 2004, 3(6):568-572.
35. Rodriguez B.A., Cheng A.S., Yan P.S., Potter D., Agosto-Perez F.J., Shapiro C.L., et al. Epigenetic repression of the estrogen-regulated Homeobox B13 gene in breast cancer. Carcinogenesis 2008, 29(7):1459-1465.
36. Edelman M.J., Smith R., Hausner P., Doyle L.A., Kalra K., Kendall J., et al. trial of the novel retinoid, bexarotene, and gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 2005, 23(24):5774-5778.
37. Yamane A., Tsukamoto N., Saitoh T., Uchiumi H., Handa H., Karasawa M., et al. Successful treatment by all-trans retinoic acid in a patient with acute promyelocytic leukemia complicated by liver cirrhosis and polycystic kidney. Intern Med 2009, 48(18):1691-1694.
38. Blaese M.A., Santo-Hoeltje L., Rodemann H.P. CRABP I expression and the mediation of the sensitivity of human tumour cells to retinoic acid and irradiation. Int J Radiat Biol 2003, 79(12):981-991.
39. Wu Q., Lothe R.A., Ahlquist T., Silins I., Trope C.G., Micci F., et al. DNA methylation profiling of ovarian carcinomas and their in vitro models identifies HOXA9, HOXB5, SCGB3A1, and CRABP1 as novel targets. Mol Cancer 2007, 6:45.
40. Tanaka K., Imoto I., Inoue J., Kozaki K., Tsuda H., Shimada Y., et al. Frequent methylation-associated silencing of a candidate tumor suppressor, CRABP1, in esophageal squamous-cell carcinoma. Oncogene 2007, 26(44):6456-6468.
41. Morgensztern D., McLeod H.L. PI3K/Akt/mTOR pathway as a target for cancer therapy. Anticancer Drugs 2005, 16(8):797-803.
42. Miller T.W., Rexer B.N., Garrett J.T., Arteaga C.L. Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer. Breast Cancer Res 2011, 13(6):224.
43. Klionsky D.J. The molecular machinery of autophagy: unanswered questions. J Cell Sci 2005, 118(Pt 1):7-18.
44. Edinger A.L., Thompson C.B. Defective autophagy leads to cancer. Cancer Cell 2003, 4(6):422-424.
45. Klionsky D.J., Emr S.D. Autophagy as a regulated pathway of cellular degradation. Science 2000, 290(5497):1717-1721.
46. Katayama M., Kawaguchi T., Berger M.S., Pieper R.O. DNA damaging agent-induced autophagy produces a cytoprotective adenosine triphosphate surge in malignant glioma cells. Cell Death Differ 2007, 14(3):548-558.
47. Lv Q., Wang W., Xue J., Hua F., Mu R., Lin H., et al. DEDD interacts with PI3KC3 to activate autophagy and attenuate epithelial-mesenchymal transition in human breast cancer. Cancer Res 2012, 72(13):3238-3250.
48. Kirchhoff S., Hauser H. Cooperative activity between HER oncogenes and the tumor suppressor IRF-1 results in apoptosis. Oncogene 1999, 18(25):3725-3736.
49. Ruiz-Ruiz C., Munoz-Pinedo C., Lopez-Rivas A. Interferon-gamma treatment elevates caspase-8 expression and sensitizes human breast tumor cells to a death receptor-induced mitochondria-operated apoptotic program. Cancer Res 2000, 60(20):5673-5680.
50. Habif D.V., Ozzello L., De Rosa C.M., Cantell K., Lattes R. Regression of skin recurrences of breast carcinomas treated with intralesional injections of natural interferons alpha and gamma. Cancer Invest 1995, 13(2):165-172.
51. Seymour L., Bezwoda W.R. Interferon plus tamoxifen treatment for advanced breast cancer: in vivo biologic effects of two growth modulators. Br J Cancer 1993, 68(2):352-356.
52. Soh J., Donnelly R.J., Kotenko S., Mariano T.M., Cook J.R., Wang N., et al. Identification and sequence of an accessory factor required for activation of the human interferon-gamma receptor. Cell 1994, 76(5):793-802.
53. Garcia-Tunon I., Ricote M., Ruiz A.A., Fraile B., Paniagua R., Royuela M. Influence of IFN-gamma and its receptors in human breast cancer. BMC Cancer 2007, 7:158.